Publicaciones en colaboración con investigadores/as de Kliniken Essen-Mitte (3)

2020

  1. Pembrolizumab for early triple-negative breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 9, pp. 810-821

2019

  1. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial

    JAMA Oncology, Vol. 5, Núm. 11, pp. 1556-1563

2018

  1. Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial

    Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3126-3133